Azuma J - Search Results

1

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, Okuda Y, Takashima T, Kamimura S, Fujio Y, Kawase I; Pharmacogenetics-based tuberculosis therapy research group. Azuma J, et al. Eur J Clin Pharmacol. 2013 May;69(5):1091-101. doi: 10.1007/s00228-012-1429-9. Epub 2012 Nov 14. Eur J Clin Pharmacol. 2013. PMID: 23150149 Free PMC article. Clinical Trial.

2

Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.

Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J. Kubota R, et al. Among authors: azuma j. Eur J Clin Pharmacol. 2007 Oct;63(10):927-33. doi: 10.1007/s00228-007-0333-1. Epub 2007 Jul 31. Eur J Clin Pharmacol. 2007. PMID: 17665185 Clinical Trial.

3

Chronic heart failure: beta-blockers and pharmacogenetics.

Azuma J, Nonen S. Azuma J, et al. Eur J Clin Pharmacol. 2009 Jan;65(1):3-17. doi: 10.1007/s00228-008-0566-7. Epub 2008 Oct 7. Eur J Clin Pharmacol. 2009. PMID: 18839161 Review.

4

[Genetic testing].

Azuma J, Nonen S. Azuma J, et al. Nihon Rinsho. 2007 Apr 28;65 Suppl 4:455-9. Nihon Rinsho. 2007. PMID: 17508579 Review. Japanese. No abstract available.

5

Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.

Ohno M, Yamamoto A, Ono A, Miura G, Funamoto M, Takemoto Y, Otsu K, Kouno Y, Tanabe T, Masunaga Y, Nonen S, Fujio Y, Azuma J. Ohno M, et al. Among authors: azuma j. Eur J Clin Pharmacol. 2009 Nov;65(11):1097-103. doi: 10.1007/s00228-009-0685-9. Epub 2009 Jul 7. Eur J Clin Pharmacol. 2009. PMID: 19582440

6

Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.

Yamada T, Nakayama M, Shimizu T, Nonen S, Nakai Y, Nishimura K, Fujio Y, Okuyama A, Azuma J, Nonomura N. Yamada T, et al. Among authors: azuma j. Int J Clin Oncol. 2013 Aug;18(4):711-7. doi: 10.1007/s10147-012-0430-8. Epub 2012 Jun 21. Int J Clin Oncol. 2013. PMID: 22714708

7

Future of pharmacogenetics-based therapy for tuberculosis.

Matsumoto T, Ohno M, Azuma J. Matsumoto T, et al. Among authors: azuma j. Pharmacogenomics. 2014 Apr;15(5):601-7. doi: 10.2217/pgs.14.38. Pharmacogenomics. 2014. PMID: 24798717 Review.

8

Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.

Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, Ito M, Yamamoto Y, Ogura T, Maeda K, Komuta K, Igarashi T, Azuma J. Ohno M, et al. Among authors: azuma j. Int J Tuberc Lung Dis. 2000 Mar;4(3):256-61. Int J Tuberc Lung Dis. 2000. PMID: 10751073

9

No positive association between adrenergic receptor variants of alpha2cDel322-325, beta1Ser49, beta1Arg389 and the risk for heart failure in the Japanese population.

Nonen S, Okamoto H, Akino M, Matsui Y, Fujio Y, Yoshiyama M, Takemoto Y, Yoshikawa J, Azuma J, Kitabatake A. Nonen S, et al. Among authors: azuma j. Br J Clin Pharmacol. 2005 Oct;60(4):414-7. doi: 10.1111/j.1365-2125.2005.02447.x. Br J Clin Pharmacol. 2005. PMID: 16187973 Free PMC article.

10

Regulation of cytochrome P450 2E1 under hypertonic environment through TonEBP in human hepatocytes.

Ito T, Asakura K, Tougou K, Fukuda T, Kubota R, Nonen S, Fujio Y, Azuma J. Ito T, et al. Among authors: azuma j. Mol Pharmacol. 2007 Jul;72(1):173-81. doi: 10.1124/mol.106.033480. Epub 2007 Apr 17. Mol Pharmacol. 2007. PMID: 17440116

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

372 results

Search Page

Filters